Genetically modified human CD4(+) T cells can be evaluated in vivo without lethal graft-versus-host disease.

@article{Ali2016GeneticallyMH,
  title={Genetically modified human CD4(+) T cells can be evaluated in vivo without lethal graft-versus-host disease.},
  author={Riyasat Ali and Jeffrey M Babad and Antonia Follenzi and John A. Gebe and Michael A. Brehm and Gerald T Nepom and Leonard D Shultz and Dale L. Greiner and Teresa P DiLorenzo},
  journal={Immunology},
  year={2016},
  volume={148 4},
  pages={339-51}
}
Adoptive cell immunotherapy for human diseases, including the use of T cells modified to express an anti-tumour T-cell receptor (TCR) or chimeric antigen receptor, is showing promise as an effective treatment modality. Further advances would be accelerated by the availability of a mouse model that would permit human T-cell engineering protocols and proposed genetic modifications to be evaluated in vivo. NOD-scid IL2rγ(null) (NSG) mice accept the engraftment of mature human T cells; however… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 2 times. VIEW TWEETS